The race for vaccines has already started. Russian Direct Investment Fund (RDIF) has signed a treaty with Delhi-based pharmaceutical company Mankind Pharma for marketing and distribution of its Sputnik V vaccine, two specialists in the know of the matter said. “It depends on how many doses they will give Mankind. RDIF has pacts with Russian and Korean manufacturers for around 50 million doses so far. Talks with Indian manufacturers are also ongoing."
Airline between India and Bangladesh will resume after 8 months
"Mankind will get the doses once the approvals are in place and the doses are supplied," one of the sources said, adding that a formal announcement is likely to be made later this week. Inquiries sent to Mankind Pharma were ignored at the time of publishing. A spokesperson for RDIF decline to comment on the development. The pact with Mankind Pharma is expected to supplement the one with Dr. Reddy’s Laboratories, but unlike Dr Reddy’s, Mankind will not be conducting the clinical trials.
No change in Petrol-Diesel price, know today's rates
Last month, Dr. Reddy’s and RDIF, Russia’s sovereign wealth fund, had entered into a partnership to conduct clinical trials of Sputnik V vaccine and its distribution in India. Under the pact, RDIF will supply 100 million doses of the vaccine to Dr Reddy’s upon regulatory approval in India. The new partnerships come on the back of an announcement by Dr Reddy’s on Saturday that they have received approval from the Drug Controller General of India (DCGI) VG Somani to conduct an adaptive phase 2 and 3 clinical trial for the Sputnik V vaccine in India.
